Skip to main content
NAMS
NASDAQ Life Sciences

European Commission Approves Obicetrapib as First-in-Class LDL-C Therapy

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$22.82
Mkt Cap
$2.688B
52W Low
$21.02
52W High
$42.205
52W Position info
8.6% above low
Off High info
46% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

NAMS is trading near its 52-week low of $21.02 (8.6% above the low).

Summary

The European Commission granted marketing authorization for Ubeslo (obicetrapib 10 mg monotherapy) and Evlarco (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination), marking the first global regulatory approval of obicetrapib. The authorizations apply across all EU Member States, Iceland, Liechtenstein, and Norway, for primary hypercholesterolaemia (HeFH/non-familial) or mixed dyslipidaemia. This follows the CHMP positive opinion in July and is supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials showing LDL-C reductions up to 40% (monotherapy) and 50% (combination) with placebo-like tolerability. Menarini holds exclusive European commercialization rights and is responsible for regulatory interactions and commercialization activities in the region, while NewAmsterdam is entitled to tiered double-digit royalties ranging from low double-digits to mid-twenties on net sales plus up to €833 million in milestones. The EC approval triggers milestone payments in the mid-teens of millions of euros to NewAmsterdam under its Menarini licensing agreement. The EC requires a post-authorization efficacy study mandating submission of final PREVAIL trial results, as well as customary post-approval safety monitoring, pharmacovigilance activities, and risk-minimization measures. The approval validates the drug's commercial pathway in Europe and de-risks the broader obicetrapib franchise ahead of the PREVAIL cardiovascular outcomes trial readout, a placebo-controlled, double-blind, randomized trial evaluating obicetrapib monotherapy as adjunct to maximally tolerated lipid-lowering therapies to potentially enhance low-density lipoprotein cholesterol lowering in patients with atherosclerotic cardiovascular disease and/or HeFH.

Updated with an SEC 8-K filing · What changed

Updates

  1. · SEC 8-K — The EC approval triggers milestone payments in the mid-teens of millions of euros to NewAmsterdam under its Menarini licensing agreement.

    • Approved Products — Ubeslo is obicetrapib 10 mg monotherapy; Evlarco is 10 mg obicetrapib plus 10 mg ezetimibe. Approved for primary hypercholesterolaemia (HeFH/non-familial) or mixed dyslipidaemia.
    • Territory — Authorizations apply across all EU Member States, Iceland, Liechtenstein, and Norway.
    • Post-Authorization Requirements — EC requires post-authorization efficacy study, mandating submission of final PREVAIL trial results. EC authorization requires customary post-approval safety monitoring, pharmacovigilance activities, and risk-minimization measures.
    • Commercialization — Menarini is responsible for regulatory interactions and commercialization activities in the region. Tiered double-digit royalties range from low double-digits to mid-twenties on net sales.
    • PREVAIL Trial — PREVAIL trial is placebo-controlled, double-blind, randomized, evaluating obicetrapib monotherapy as adjunct to maximally tolerated lipid-lowering therapies. PREVAIL trial aims to potentially enhance low-density lipoprotein cholesterol lowering in patients with atherosclerotic cardiovascular disease and/or HeFH.
    All 9 details
    • Ubeslo is obicetrapib 10 mg monotherapy; Evlarco is 10 mg obicetrapib plus 10 mg ezetimibe.
    • Approved for primary hypercholesterolaemia (HeFH/non-familial) or mixed dyslipidaemia.
    • Authorizations apply across all EU Member States, Iceland, Liechtenstein, and Norway.
    • EC requires post-authorization efficacy study, mandating submission of final PREVAIL trial results.
    • Menarini is responsible for regulatory interactions and commercialization activities in the region.
    • Tiered double-digit royalties range from low double-digits to mid-twenties on net sales.
    • EC authorization requires customary post-approval safety monitoring, pharmacovigilance activities, and risk-minimization measures.
    • PREVAIL trial is placebo-controlled, double-blind, randomized, evaluating obicetrapib monotherapy as adjunct to maximally tolerated lipid-lowering therapies.
    • PREVAIL trial aims to potentially enhance low-density lipoprotein cholesterol lowering in patients with atherosclerotic cardiovascular disease and/or HeFH.

At the time of this announcement, NAMS was trading at $22.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $21.02 to $42.21. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

NAMS - Latest Insights

NAMS
Nov 04, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.69
Real-time Price: $19.50 info
Change: -$1.19 (-6%) info
Market Cap: $2.334B info
NAMS
Nov 04, 2026, 7:31 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.24
Real-time Price: $19.50 info
Change: -$0.740 (-4%) info
Market Cap: $2.334B info
NAMS
Sep 29, 2026, 8:22 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.71
Real-time Price: $19.50 info
Change: -$4.21 (-18%) info
Market Cap: $2.334B info
NAMS
Sep 22, 2026, 4:58 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $23.32
Real-time Price: $19.50 info
Change: -$3.82 (-16%) info
Market Cap: $2.334B info
NAMS
Aug 05, 2026, 7:08 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.52
Real-time Price: $19.50 info
Change: -$8.02 (-29%) info
Market Cap: $2.334B info